CJC-1295 (No DAC) vs Ipamorelin
Written by the Pure Peptides editorial team
Reviewed by Dr. Martina Rossi, PhD
Scientific Contributor and Reviewer · Reviewed
Published · Updated · 8 references
CJC-1295 (No DAC) and Ipamorelin are different molecules: CJC-1295 (No DAC) is a synthetic peptide built on human GHRH's first 29 residues, and Ipamorelin is a synthetic five-residue peptide.
Structure at a glance
CJC-1295 (No DAC) · 29 residues
Ipamorelin · 5 residues
NH2: C-terminal amide. A raised D marks a D-amino acid. 2Nal: 2-naphthylalanine. Aib: alpha-aminoisobutyric acid. Codes are three-letter amino acid codes.
Drawn from the product database. Each measure's bars share one scale.
| Property | CJC-1295 (No DAC) | Ipamorelin |
|---|---|---|
| What it is | A synthetic analog of growth hormone-releasing hormone. Built on the GRF(1-29) backbone, with four amino acid substitutions.[1] | A synthetic five-residue peptide that does not correspond to any natural peptide sequence. |
| How they relate | Different molecules. CJC-1295 (No DAC) is a synthetic peptide built on human GHRH's first 29 residues, with four substitutions. Ipamorelin is a synthetic construct that does not correspond to any natural peptide sequence. | |
| CAS number | 446036-97-1 | 170851-70-4 |
| Molecular formula | C152H252N44O42 | C38H49N9O5 |
| Molecular weight | 3,367.97 g/mol | 711.85 g/mol |
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 | Aib-His-D-2Nal-D-Phe-Lys-NH2 |
| Evidence base | In the literature reviewed for CJC-1295 (No DAC), the pharmacokinetic findings were generated with the DAC form. Essentially uncharacterized in humans.[2] | Three published human studies. One was a pharmacokinetic-pharmacodynamic study in healthy male volunteers.[3] A randomized phase 2 trial missed its key endpoint and its secondary analyses.[4] The third tracked its breakdown products in one volunteer's urine.[7] |
| Regulatory status | The FDA has not approved CJC-1295 (No DAC) for human use. | The FDA has not approved Ipamorelin for human use. |
| Compared head-to-head? | No direct comparison found in PubMed (searched October 2026).[5] | |
| Handling difference | Neither contains sulfur, so neither has a cysteine or a methionine. | |
How CJC-1295 (No DAC) and Ipamorelin differ
CJC-1295 (No DAC) and Ipamorelin are different molecules. CJC-1295 (No DAC) is a synthetic 29-residue peptide corresponding to the first 29 positions of human growth hormone-releasing hormone (GHRH), with four of those positions substituted. It is also sold as Modified GRF(1-29), a name that states that construction more plainly. Ipamorelin is a synthetic five-residue peptide that does not correspond to any natural peptide sequence.
In the literature reviewed for CJC-1295 (No DAC), the pharmacokinetic findings, in rats and healthy volunteers, came from CJC-1295 with DAC, whose albumin-binding linker CJC-1295 (No DAC) lacks. CJC-1295 (No DAC) itself is essentially uncharacterized in humans.[2] The literature reviewed for CJC-1295 (No DAC) reports no human safety data for CJC-1295 (No DAC) itself. The literature reviewed for Ipamorelin includes three published human studies. One was an early-phase pharmacokinetic-pharmacodynamic study in healthy male volunteers.[3] The other was a randomized phase 2 trial of 114 participants, in one indication, and it missed its key endpoint and its secondary analyses.[4] The third, a 2015 anti-doping laboratory study, tracked its breakdown products in one volunteer's urine for two days.[7] Almost everything else known about Ipamorelin comes from preclinical pharmacology. Much of the defining preclinical work comes from the original developer, which raises the usual question of independent replication. FDA's 2024 review of the phase 2 trial records serious adverse events in 10 of 56 patients given Ipamorelin and 9 of 58 given placebo.[8] Two patients given Ipamorelin died after colon cancer surgery complicated by a leak where the bowel was rejoined.[8] FDA states it is unclear whether the deaths were related to Ipamorelin.[8]
Neither compound holds a US approval. FDA's 2024 review found no approved product containing any form of CJC-1295 in the United States, the European Union or 12 other countries.[6] The FDA has not approved Ipamorelin for human use.
CJC-1295 (No DAC) contains no sulfur, so it carries neither cysteine nor methionine. Its other chemical liabilities include aspartate, which can isomerize, and glutamine, which can deamidate. Ipamorelin also contains no sulfur. Its remaining liabilities are general: amide hydrolysis under strong acid or alkali, slow near neutral pH, and oxidation of its aromatic side chains.
Have CJC-1295 (No DAC) and Ipamorelin been compared directly?
No direct comparison of CJC-1295 (No DAC) with Ipamorelin was found in a PubMed search run in October 2026.[5] That search covers PubMed only.
Read more on each compound
CJC-1295 (No DAC)
Frequently Asked Questions
Is CJC-1295 (No DAC) the same as Ipamorelin?+−
CJC-1295 (No DAC) and Ipamorelin are different molecules. CJC-1295 (No DAC) is a synthetic 29-residue peptide built on the first 29 positions of human growth hormone-releasing hormone, with four of them substituted. Ipamorelin is a synthetic five-residue peptide that does not correspond to any natural peptide sequence.
References
- 1Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286. PMID 15817669.
- 2Dominikowski A, et al. Front Endocrinol (Lausanne) 2026. PMID 42395176. DOI 10.3389/fendo.2026.1822475. Narrative review.
- 3Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharm Res. 1999;16(9):1412-6. doi:10.1023/a:1018955126402. PMID 10496658.
- 4Beck DE, Sweeney WB, McCarter MD. 2014;29(12):1527-1534. doi:10.1007/s00384-014-2030-8. PMID 25331030.
- 5
PubMed search, 3 October 2026 (records to 2 October 2026)
11 records; none was a direct comparison of the two compounds.
Exact query (NCBI E-utilities): ("CJC-1295"[tiab] OR "CJC 1295"[tiab] OR "CJC1295"[tiab] OR "modified GRF"[tiab] OR "mod GRF"[tiab] OR "modGRF"[tiab] OR "tetrasubstituted"[tiab] OR "DAC-free"[tiab] OR "non-DAC"[tiab] OR "without DAC"[tiab] OR "no DAC"[tiab]) AND ("ipamorelin"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])
View this search on PubMed - 6US Food and Drug Administration, Center for Drug Evaluation and Research. Briefing document, 4 December 2024. Regulatory document, not peer-reviewed. fda.gov
- 7Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G. Drug Test Anal. 2015;7(10):919-25. doi:10.1002/dta.1787. PMID 25869809. Anti-doping laboratory study.
- 8US Food and Drug Administration, Center for Drug Evaluation and Research. Briefing document, 29 October 2024, section on clinical studies assessing safety. Regulatory document, not peer-reviewed. fda.gov

Reviewed for scientific accuracy
Dr. Martina Rossi, PhD
PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer
Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.
Related comparisons
CJC-1295 (No DAC) vs CJC-1295 with DAC
CJC-1295 with DAC is a chemically modified form of CJC-1295 (No DAC); the DAC-free peptide is essentially uncharacterized in humans.
Read ComparisonCJC-1295 (No DAC) vs IGF-1 LR3
CJC-1295 (No DAC), a 29-residue peptide, and IGF-1 LR3, an 83-residue protein, are different molecules from different parents.
Read ComparisonCJC-1295 (No DAC) vs Sermorelin
CJC-1295 (No DAC) is human GHRH's first 29 residues with four substitutions; Sermorelin is the unmodified fragment.
Read Comparison

